by Kathy Jones on  August 31, 2012 at 7:58 PM Drug News
 Teva’s Neutropenia Drug Approved by FDA
The US Food and Drug Administration has revealed that it has approved Teva Pharmaceutical Industries' neutropenia drug that will help increase the production of infection-fighting white blood cell among patients who are undergoing chemotherapy.

With Amgen's patent for its biologic drug Neupogen expiring next year; the FDA has approved Teva's tbo-filgrastim, which is similar to Neupogen. However Teva will not be able to market its drug until November 2013 following a settlement of patent litigation with Amgen last year.


Stating that the drug may help patients recover faster from neutropenia, FDA's Richard Pazdur said, "Supportive care products, such as tbo-filgrastim, reduce or allow for more rapid recovery from side effects of cancer treatments."

Source: Medindia

Most Popular on Medindia